NCT00038623View on ClinicalTrials.gov

Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

December 31, 2007

Study Completion Date

February 28, 2010

Conditions
Lymphoma, Mantle-Cell
Interventions
DRUG

Yttrium-ibritumomab (Zevalin)

After Rituximab infusion, 111\^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.

DRUG

Rituximab

250 mg/m\^2 in the vein over 6 to 8 hours on Day 1.

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER